https://sciex.com/content/SCIEX/na/us/en

AB Sciex is doing business as SCIEX. © 2010-2018 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license. Beckman Coulter® is being used under license. Product(s) may not be available in all countries. For information on availability, please contact your local representative. For research use only. Not for use in diagnostic procedures.

<a href="https://community.sciex.com/author/commmunitysuperuser/" target="_self">SCIEX Community</a>

SCIEX Community

Facebook
X (Twitter)
LinkedIn
Share


Glycosylation Analysis Designed for the (Protein) Masses

Nov 9, 2016 | Biopharma, Blogs | 0 comments

A variety of post-translational modifications (PTMs) can impact a biotherapeutic protein’s mass, but none are as common as glycosylation.[1] Hence, the headline for a recent article in Genetic Engineering and Biotechnology News,  “Post-Translational Icing on the Biologics Cake,” featuring comments from Sean McCarthy, Ph.D., Global Market Manager of Biologics at SCIEX.

About the Article: Biotherapeutic protein glycosylation plays a key role in whether or not a biologic drug can effectively treat disease, making the detection and characterization of these glycan structures an important topic for pharmaceutical developers.  Dr. McCarthy gives his take on using different liquid chromatography separation techniques together with mass spectrometry to go after low-level immunogenic glycan epitopes on biotherapeutics, which could elicit an undesirable immune response in patients. The development of  focused instrumentation and software solutions to meet the needs of biologics characterization workflows are profiled in this article, with a focus on the SCIEX TripleTOF® 6600 MS system coupled with BioPharmaView™ software. Together, the TripleTOF system and BioPharmaView software can profile intact protein glycoforms, or comprehensively identify and quantitate specific glycopeptides.Read the Article >

Want to Know More about Glycan Analysis?

Discover innovations with this useful ‘Glycan Analysis Solution Guide’ that helps you:

  • Resolve microheterogeneity and profile glycans
  • Prep and analyze 96 glycan samples in <6 hours
  • Characterize glycosylated proteins using LC-MS technology
  • Detect low abundance glycan forms with CESI-MS
  • Access notable publications and webinars

About Dr. McCarthy:
Sean M. McCarthy received his degree in Chemistry from the University of Vermont in 2005, followed by his NIH postdoctoral associate within the Department of Pathology at the same institution. His work centered on environmental oxidative stress related diseases using a variety of biochemical and mass spectrometric techniques. Dr. McCarthy has worked in the mass spectrometry industry since 2008 and has held several scientific and business development positions to address pharmaceutical and biopharmaceutical characterization. Dr. McCarthy is currently the Global Market Manager of Biologics at SCIEX, where his focus is on delivering targeted solutions for biopharmaceutical characterization.

[1] http://www.sciencedirect.com/science/article/pii/S135964461600026X

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

Community Manager
Tags
Biopharmabiotherapeutic developmentblazechargecompanycoupledevelopmentjobmachinemassmoneynewnumberpowerproteinrapidsystemtechnologytimevariantwork

0 Comments

Submit a Comment

SCIEX Now™ Support Network

The Destination for All Your Support Needs

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.
Empower is a trademark of Waters Corporation used under license. © DH Tech. Dev. Pte. Ltd.

Wordpress Social Share Plugin powered by Ultimatelysocial